Seizure Disorders Clinical Trial
— FruitiVitsOfficial title:
A Taste and Acceptance Study of FruitiVits, for Use in the Dietary Management of Young Children Requiring Very Restrictive Diets Such as the Ketogenic Diet.
Verified date | February 2024 |
Source | Vitaflo International, Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Subjects will be asked to substitute their usual vitamin and mineral supplement/s with FruitiVits for seven consecutive days.
Status | Completed |
Enrollment | 11 |
Est. completion date | October 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years to 9 Years |
Eligibility | Inclusion Criteria: 1. Diagnosis of condition requiring a Ketogenic diet 2. Currently on a Ketogenic diet 3. Aged 4 - 8 years 4. Routinely taking a complete micronutrient supplement 5. Oral feeding Exclusion Criteria: 1) Children aged less than 4 years or older than 9 years of age |
Country | Name | City | State |
---|---|---|---|
United States | The Children's Hospital of Philadelphia, Division of Neurology | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Vitaflo International, Ltd | Children's Hospital of Philadelphia |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acceptability of FruitiVits | The study product was rated on a scale of 1-5:
(liked very much) (liked moderately) (neither liked nor disliked) (disliked moderately) (disliked very much). |
Day 8 of trial | |
Secondary | Ease of Preparation of FruitiVits | Ease of preparation of FruitiVits was rated on a scale of 1-5:
(very easy) (moderately easy) (neither easy nor difficult) (moderately difficult) (very difficult). Those who considered it not difficult to prepare and scored 1-3 on the scale: 11/11 patients |
Day 8 of trial |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01159431 -
External Trigeminal Nerve Stimulation for Epilepsy
|
Phase 2 | |
Completed |
NCT01116700 -
Dexmedetomidine in Seizure Patients
|
Phase 1 |